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SUMMARY  
 
Cardiovascular disease (CVD) is the leading cause of mortality among men and women 
in Europe. Somatic risk factors, including hypertension, obesity and type II diabetes mellitus 
(T2DM) have been established as having the largest role in the incidence of CVD. However, 
while research continues to shed light on the pathogenesis, etiology, treatment and management 
of risk factors, psychosocial factors have not received the required attention.    
The current doctoral thesis aims to provide a real-world perspective of the association 
between somatic risk factors and depressed-mood, and the consecutive impact on the incidence 
of T2DM and CVD. The investigations were derived from two published manuscripts using 
population-based prospective data from Augsburg, Southern Germany. The first manuscript 
examined the 10-year CVD mortality in participants with hypertension cut-off values according 
to the current European Society of Cardiology (ESC), in comparison to the recently proposed 
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines. 
Departure from the current ESC to the ACC/AHA hypertension cut-off substantially increased 
the hypertension prevalence, while capturing a population with lower CVD risk. Furthermore, 
participants who were aware of their hypertension had higher depressed-mood in comparison 
to those who were unaware, reflecting a negative labelling effect. The second manuscript 
examined the interactive effects of obesity and depressed-mood on the 15-year risk of incident 
T2DM, aiming to understand whether depressed mood had an additional impact for prognosis 
of morbidity in obese people. The investigation disclosed that despite the significance of obesity 
as a risk factor for T2DM, presence of depressed-mood heightened the T2DM risk even further 
in obese people.  
The current thesis highlights the relevance of psychosocial factors, namely, depressed-
mood, in clinical settings and for public health intervention efforts for CVD and T2DM. 
Depressed-mood is an essential psychosocial factor to consider in future aetiological 
conceptualizations of CVD and T2DM because it reveals mortality and morbidity risk beyond 
the traditional risk factors while simultaneously representing the quality of life of the individual.   
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1. INTRODUCTION   
 
Cardiovascular disease (CVD) is the leading cause of global mortality, accountable for 
32% of all deaths worldwide1,2, as well as 43.6% of deaths in women and 36.1% of deaths in 
men in Germany3. Beginning with the Framingham Heart Study in 1945, considerable research 
has been conducted to establish the risk factors of CVD4. Ultimately, the INTERHEART case 
trial found that six major risk factors can be accountable for nine out of ten cases resulting in 
myocardial infarction; including dyslipidemia, smoking, hypertension, diabetes mellitus, 
obesity and adverse psychosocial factors5. However, despite the advances in the field, the risk 
prediction of CVD remains low, particularly in individuals with low or intermediate risks6,7. 
Among the classic risk factors of CVD, hypertension takes the lead. Currently, 
hypertension is defined by the ECS as systolic blood pressures values of 140-159 mmHg and/or 
diastolic blood pressure values of 90-99 mmHg8. Hypertension is independently responsible for 
54% of stroke and 47% of ischemic heart disease worldwide9. However, despite being a major 
and modifiable risk factor for the onset of CVD, a review of population studies from 90 
countries showed that the prevalence of hypertension increased from 26% in 2000 to 31% in 
201010. Additionally, 53.5% of the global population remained unaware of their hypertension, 
and although this value is 33% in high-income countries, it still remains alarming. Similarly, 
global antihypertensive treatment increased by only 5% (31.8-36.9%), and by 10% in high-
income countries (44.5 to 55.6%). In Germany, treatment of hypertension also showed a 
comparable increasing trend, and hypertensive patients below 55-years remain largely 
untreated11. Hence, to decrease the global impact of hypertension, the ACC/AHA aimed to 
reclassify hypertension in 2017 by lowering the hypertension cut-off to systolic blood pressure 
values of 130-139 mmHg and/or diastolic blood pressure values of 80-89 mmHg12. The purpose 
of the reclassification was to increase awareness and begin earlier antihypertensive treatment; 
however, real-world consequences remain to be studied. For instance, in a population-based 
study including 33,105 participants from England, an awareness of hypertension was associated 
with psychological distress, including depression, irrespective of actual blood pressure values 
or antihypertensive treatment status13.   
Similarly, detrimental links between CVD and type II diabetes have been revealed by a 
meta-analysis of 102 prospective studies including data from 698,782 participants, where 
diabetes increased the risk of CVD by 2-fold, independently of additional risk factors14 As the 
global prevalence of T2DM increased from 4.3% to 9.0% in men and 5.0 to 7.9% in women 
between 1980 and 201415, and continues to effect 9.9% of the population in Germany16, 
etiological pathways of T2DM require further attention. Moreover, data from the 
MONICA/KORA cohort used in the current investigations aim to underline the challenge that 
people with T2DM need intensive preventive interventions to reduce risk of CVD17. Obesity, 
defined as a body mass index of 30 or more, accounts for the majority of T2DM risk18. In line 
with the high prevalence of T2DM in Germany, it corresponds that it is the 8th most obese 
country in the world19, with over 23% of the population affected20. Furthermore, the prevalence 
of obesity in Germany has risen by 1.4% in women and 4.4% in men in the last decade, 
continuing towards an upward trend20. However, despite the rising levels of obesity, much 
remains unknown regarding inter-individual differences for management and treatment for 
better health prognoses. For instance, recent evidence shows that finding clustered classification 
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among obese people can allow for individually tailored and more effective interventions – obese 
people who are considered metabolically healthy might have lower risk of morbidity and 
mortality21-23. Additionally, the many psychosocial facets of obesity24,25 calls into question the 
effect of obesity on T2DM risk that can be accounted for by obesity alone. Hence, psychosocial 
phenotypes of obesity might prove effective in shaping targeted interventions aimed at 
decreasing the incidence of T2DM and ultimately CVD.  
Adverse psychosocial factors have been recognized as significant risk factors of CVD5. 
Among these psychosocial factors, depression has gained utmost attention, increasing CVD risk 
between 60-90%26-30 due to multifactorial pathological mechanisms31. As depression is a 
common mental health disorder with a global prevalence of 4.4 % or 300 000 million people 
32) and effecting 10.2% of women and 6.1% of men in Germany33, further understanding of the 
connection between depression and other classic risk factors is required. Thus far, depression 
as a risk factor of CVD and T2DM34 has three additional implications. Previous research has 
established that depression additionally increases the risk of  hypertension35 and obesity36. 
Moreover,  the relationship is bidirectional - the presence of hypertension13 and obesity36 also 
increases the risk of depression. Lastly, among people with CVD37and T2DM38, a negative 
impact in prognosis of disease have been found. Despite the implications, depression is not 
likely to be identified in primary care, and the risks of comorbidity with existing risk factors 
might go unnoticed due to lack of adequate treatment.   
2. RATIONALE AND METHODS 
 
2.1 Aims 
  
The current doctoral thesis aims to investigate the hypothesis that depressed mood is 
associated with heightened adverse effects of CVD and T2DM, in interaction with or even 
beyond the major classic risk factors; namely, hypertension and obesity. Specifically, 
manuscript 1 aims to examine the association of the ECS and AHA classifications of 
hypertension, corresponding labeling effects as assessed by depressed-mood, and future risk of 
CVD mortality. Manuscript 2 further aims to examine the association between depressed-mood, 
obesity and their additive effect on the risk of T2DM.   
 
2.2. Study Population  
 
2.2.1 Baseline Data 
 
The data in the current investigations are derived from 13,426 participants who took part in one 
of three cross-sectional surveys as part of the Monitoring of Trends and Determinants in 
Cardiovascular Disease Augsburg (MONICA) project39, as can be seen in Figure 1. The cross-
sectional surveys were conducted by the World Health Organization (WHO) in 1984/85, 
1989/90, and 1994/95 through standardized interviews by trained medical staff, a self-
administered questionnaire, and medical examination. Written informed consent was obtained 
from each study participant and the study was approved by the local ethics committee. 
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Figure 1. The participant flow from baseline S1-S4 KORA studies to the GEFU follow up.  
 
2.2.2 Follow-up 
The General Morbidity Follow up (GEFU) was within the framework of the Cooperative 
Health Research in the Region of Augsburg and conducted periodically (Figure 1). In 
Manuscript 1, T2DM incidence was assessed using GEFU 2008/2009 by self-report and 
further validated through hospital records or by contact with physicians. In Manuscript 2, 
GEFU 2001/2002 was used to assess CVD mortality. Certificates were obtained from local 
health departments and coded for the underlying cause of death by a single trained person 
using the 9th revision of the International Classification of Diseases (ICD-9).   
2.2.3. Statistical Analyses 
For all analyses, a p value < 0.05 was considered to be statistically significant. All statistical 
evaluations were performed using SAS (version 9.3). The analyses and descriptions in this 
manuscript follow the STROBE guidelines for cohort studies. 
 
2.2.4 Descriptive analyses 
The proportion of the population with relevant risk factors and group differences were 
calculated using the Pearson χ2 and Wilcoxon rank-sum tests. Significance of the obtained 
results were assessed using Cochran-Armitage Test for Trend.  
2.2.5 Absolute and relative risk  
The absolute risk of CVD and/or T2DM were calculated across relevant sub-population groups.  
Proportional hazards models were computed to assess the relative risks of the major risk factors 
(hypertension, obesity, depression) on CVD and type 2 diabetes endpoints. In both manuscripts, 
confounders were included in a step-wise manner to present additional risk of associated with 
the confounders. The step-wise multivariate models were adjusted for (1) age, sex, survey (2) 
life-style factors (3) metabolic or somatic factors (4) and psychosocial factors. Proportional 
hazards could be estimated by fitting models stratified by the risk factor categories and plotting 
the log-log survival curves for each risk factor, which were assessed for parallelism by visual 
inspection. As severe deviations from parallelism were not observed for any covariates, 
proportional hazards were assumed. Furthermore, in Manuscript 1, competing risks (additional 
causes of mortality) were assessed using Fine and Gray’s sub-distribution hazard models. On 
the other hand, in Manuscript 2, multiplicative and additive interaction analyses were included 
to assess the relative risk of comorbid obesity and depressed mood on the incidence of T2DM.  
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Robustness of results were scrutinized with additional sensitivity analyses within each 
manuscript.   
 
3. RESULTS  
 
Manuscript 1: Association of hypertension cut-off values with 10-year cardiovascular mortality 
and clinical consequences: a real-world perspective from the prospective MONICA/KORA 
study (S. Atasoy et al., European Heart Journal, 2018) 
Manuscript 1 showed that departure from the current ESC hypertension cut-off (Stage 
2, or S2) to the ACC/AHA hypertension cut-off (Stage 1, or S1) has increased the hypertension 
prevalence from 34% to 63% in 11,603 (52% men, 48% women; mean 47.6 years) community 
dwelling participants from the MONICA/KORA cohort. The cross-sectional analyses showed 
that only 24% of S2 hypertension patients were under pharmacological treatment. 
Correspondingly, among S2 participants, there was a significantly higher prevalence of 
depressed-mood in pharmacologically treated patients (47%) in comparison to non-treated 
patients (33%) (p<.0001).  Furthermore, within a follow-up period of 10 years (70,148 person-
years), 370 fatal CVD events were observed. The adjusted CVD-specific mortality rate /1000 
persons were 1.61 (95% CI 1.10-2.25) cases in S2 and 1.07 (95% CI 0.71-1.64) cases in S1 
hypertension in comparison to normal blood pressure. Cox proportional regression models were 
significant for the association of S2 and CVD mortality (1.54, 95% CI 1.04-2.28, p=.03), also 
in the presence of competing risks (1.47, p=.05).  However, statistical significance for S1 
hypertension was not reached (0.93, 95% CI 0.61-1.44, p=.76).  
 
Manuscript 2: Cumulative Effect of Depressed Mood and Obesity on Type II Diabetes 
Incidence: Findings from the MONICA/KORA Cohort Study (Atasoy et al. Journal of 
Psychosomatic Research, 2018) 
Manuscript 2 showed that the cumulative effect of having both obesity and depression 
leads to a significantly higher risk of type 2 diabetes. The study included 9,340 participants 
(51.6% men, 48.4% women, mean age 49.1 years) from the MONICA/KORA prospective 
study. Of these participants, 1732 (18.5%) had obesity, 3,816 (37.6%) participants had 
depressed mood, and 602 (6.4%) had both conditions. After a mean follow up period of 15.4 
years (SD ±4.7) there were 968 (10.4%) cases of T2DM incidence. Furthermore, the relative 
risk of T2DM was over 6 fold higher among obese participants in comparison to normal weight 
participants (hazard ratio: 6.05; 95% CI 4.82 to 7.59; p < .0001). Nonetheless, among 
participants with obesity, comorbidity of depression was associated with an additional 2-fold 
risk T2DM (hazard ratio: 8.05, 95% CI 5.90–10.98; p < .0001). This finding corresponded to 
an increase in the 15.4-year absolute risk of T2DM from 15.9 cases per 1000 person-years in 
participants with obesity but not depression, to 21.4 cases per 1000 person-years for participants 
with obesity and depression. Further analysis of joint effects and Relative Excess Risk due to 
Interaction disclosed that depressed mood is associated with significantly higher risk of T2DM 
in participants with obesity, and to a lesser extent in overweight participants, however an 
association was not found in normal weight participants. 
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4. CONCLUSION AND OUTLOOK  
 
In conclusion, the current doctoral thesis highlights the clinical significance of the 
current ESC hypertension cut-offs for predicting CVD mortality and the risk of obesity for the 
incidence of T2DM, while accounting for psychosocial risk factors. Within these studies, 
depressed mood was introduced and examined in both manuscripts in distinctive however 
clinically relevant ways. In Manuscript 1, depressed mood was associated with an awareness 
of hypertension at baseline, and implied that a new lower hypertension cut-off would lead to 
more depressed-mood as a direct result of the increase in hypertension prevalence. However, 
considering the insignificant risk of CVD mortality in the lower hypertension cut-off, it was 
unclear whether the potential adverse effects could be justified. On the other hand, in 
Manuscript 2, depressed-mood had a significant additive effect on the association between 
obesity and onset of T2DM, showing a clear dose-response relationship with increasing BMI 
and risk of T2DM in comparison to normal weight participants. Furthermore, this relationship 
was found to be significant on an additive scale, amplifying the relevance for public health 
interventions.  
 
 The results herein demonstrate that future investigations related to CVD need to include 
psychosocial factors for real-world applicability of somatic risk factors in terms of the 
subjective experience of individuals and the consequent effects on their quality of life. With the 
increasing awareness of the mind-body connection observed in epidemiological research, the 
expected outlook is that health care professionals will assess CVD risk in light of the 
individual’s mental state. For instance, the next step of Manuscript 1 will be to focus on the 
trajectory of baseline hypertension with onset psychosocial factors in follow up surveys from 
MONICA/KORA studies. Finally, the next step of Manuscript 2 will be to take into account 
additional psychosocial factors in obese people to discover a potential phenotype that exists in 
parallel to metabolically healthy obesity – a psychologically healthy obesity. 
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